The reduced appetite that comes along with taking a GLP-1 can make your food choices all the more important
The Danish Medicines Agency has reported 19 cases of NAION among Ozempic users in Denmark, with a noticeable increase in overall cases since the drugs market debut in 2018
Compelling evidence from landmark clinical trials, particularly STEP-HFpEF, STEP-HFpEF DM and SUMMIT, has established the efficacy of GLP-1RAs in improving HF-related symptoms and quality of life, as well as reducing worsening HF events, in the prevalent phenotype of HFpEF in the setting of obesity and T2D
Therefore, the safety profile of microdosing GLP 1 drugs is still unknown
Curr Pharm Des (2021)
For more information, visit medevidence.com, encoredocs.com or read more about ongoing obesity trials at this link here.